Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 214

1.

A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).

Forette F, Anand R, Gharabawi G.

Eur J Neurol. 1999 Jul;6(4):423-9.

PMID:
10362894
[PubMed - indexed for MEDLINE]
2.

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

Rogers SL, Doody RS, Mohs RC, Friedhoff LT.

Arch Intern Med. 1998 May 11;158(9):1021-31.

PMID:
9588436
[PubMed - indexed for MEDLINE]
3.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
[PubMed - indexed for MEDLINE]
4.

An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.

Kumar V, Anand R, Messina J, Hartman R, Veach J.

Eur J Neurol. 2000 Mar;7(2):159-69.

PMID:
10809936
[PubMed - indexed for MEDLINE]
5.
6.

An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.

Bilikiewicz A, Opala G, Podemski R, Puzyński S, Łapin J, Sołtys K, Ochudło S, Barcikowska M, Pfeffer A, Bilińska M, Paradowski B, Parnowski T, Gabryelewicz T.

Med Sci Monit. 2002 Feb;8(2):PI9-15.

PMID:
11859291
[PubMed - indexed for MEDLINE]
7.

Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.

Auriacombe S, Pere JJ, Loria-Kanza Y, Vellas B.

Curr Med Res Opin. 2002;18(3):129-38.

PMID:
12094822
[PubMed - indexed for MEDLINE]
8.

Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.

Potkin SG, Anand R, Fleming K, Alva G, Keator D, Carreon D, Messina J, Wu JC, Hartman R, Fallon JH.

Int J Neuropsychopharmacol. 2001 Sep;4(3):223-30.

PMID:
11602028
[PubMed - indexed for MEDLINE]
9.

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B.

Neurology. 1998 May;50(5):1222-30.

PMID:
9595967
[PubMed - indexed for MEDLINE]
10.

Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders.

Desai A, Grossberg G.

Expert Opin Pharmacother. 2001 Apr;2(4):653-66. Review. Erratum in: Expert Opin Pharmacother 2001 May;2(5):907.

PMID:
11336614
[PubMed - indexed for MEDLINE]
11.

Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.

Farlow M, Potkin S, Koumaras B, Veach J, Mirski D.

Arch Neurol. 2003 Jun;60(6):843-8.

PMID:
12810489
[PubMed - indexed for MEDLINE]
12.

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.

Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R.

Arch Neurol. 2001 Mar;58(3):417-22.

PMID:
11255445
[PubMed - indexed for MEDLINE]
13.

The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.

Raskind MA, Cyrus PA, Ruzicka BB, Gulanski BI.

J Clin Psychiatry. 1999 May;60(5):318-25.

PMID:
10362441
[PubMed - indexed for MEDLINE]
14.

A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease.

Imbimbo BP, Lucca U, Lucchelli F, Alberoni M, Thal LJ.

Alzheimer Dis Assoc Disord. 1998 Dec;12(4):313-22.

PMID:
9876959
[PubMed - indexed for MEDLINE]
15.

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartman R, Gharabawi M.

BMJ. 1999 Mar 6;318(7184):633-8. Erratum in: BMJ 2001 Jun 16;322(7300):1456.

PMID:
10066203
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer's disease: a prospective post-marketing surveillance study.

Chiu PY, Dai DE, Hsu HP, Lee C, Lin JJ, Kuo HC, Huang YC, Liu YC, Tsai CP.

Clin Drug Investig. 2009;29(11):729-38. doi: 10.2165/11315320-000000000-00000.

PMID:
19813776
[PubMed - indexed for MEDLINE]
17.

Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.

Cummings JL, Koumaras B, Chen M, Mirski D; Rivastigmine Nursing Home Study Team.

Am J Geriatr Pharmacother. 2005 Sep;3(3):137-48.

PMID:
16257816
[PubMed - indexed for MEDLINE]
18.

Rivastigmine in patients with Alzheimer's disease and concurrent hypertension.

Erkinjuntti T, Skoog I, Lane R, Andrews C.

Int J Clin Pract. 2002 Dec;56(10):791-6.

PMID:
12510954
[PubMed - indexed for MEDLINE]
19.

Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.

Burns A, Spiegel R, Quarg P.

Int J Geriatr Psychiatry. 2004 Mar;19(3):243-9.

PMID:
15027039
[PubMed - indexed for MEDLINE]
20.

Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.

Aupperle PM, Koumaras B, Chen M, Rabinowicz A, Mirski D.

Curr Med Res Opin. 2004 Oct;20(10):1605-12.

PMID:
15462693
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk